Absci, a startup focused on developing generative AI antibody discovery technology, announced a potential $247 million partnership with pharma giant AstraZeneca to focus on expediting the discovery of novel cancer treatments with the help of genAI technology.
The project will leverage Absci's Integrated Drug Creation platform – which combines scalable wet lab technologies with AI, and facilitates...
Philadelphia-based AI-enabled biotech company Vivodyne announced it closed a $38 million seed funding round led by Khosla Ventures.
CS Ventures, Kairos Ventures, Bison Ventures and MBX Capital also participated in the round.
WHAT IT DOES
Vivodyne is a drug discovery company that uses clinically predictive AI to help identify therapeutic targets and predict a patient's response to a drug by...
This week Israel-based AION Labs, an AI-enabled drug discovery partnership between global pharma and tech companies like AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services, announced the formation of a new startup company dubbed OMEC.AI.
OMEC.AI aims to build a computational platform using AI that can help researchers assess the clinical trial readiness of a drug...
NuraLogix introduces health measurement app in Singapore
Canadian health AI company NuraLogix has introduced its mobile health measurement app in Singapore.
Anura uses proprietary transdermal optical imaging technology, which captures blood information from a person's face through a video camera. It can measure various vital parameters, including blood pressure, heart rate, stress level, cardiac...
Tohoku University's Tohoku Medical Megabank Organization, pharmaceutical firms Daiichi Sankyo and Takeda Pharmaceutical Co., and medical IT company MICIN have started a collaborative research project to track long-term lifestyle habits to drive the creation of new drugs.
According to a press statement, the organisations will loan wearable tracking devices to about 2,000 participants. Over a year...
ICT provider Fujitsu has partnered with research institute Riken in Japan to jointly work on new-generation IT drug discovery technology to accelerate digital transformation in drug discovery.
According to a press statement, the organisations will utilise the supercomputer Fugaku, which they have developed together in the past decade, along with simulation AI technologies. Through these...
AI-enabled pathology company PathAI has entered into a multiyear drug discovery partnership with pharma giant GlaxoSmithKline.
The agreement will focus on advancing clinical trials and drug development in oncology and for nonalcoholic steatohepatitis (NASH), an aggressive type of fatty liver disease that can lead to serious scarring and liver failure.
"Our partnership will combine GSK and PathAI...
Drug discovery startup ArrePath announced Thursday it has raised $20 million in a seed funding round led by the Boehringer Ingelheim Venture Fund, Insight Partners and Innospark Ventures.
Other participants in the round include Viva BioInnovator, Arimed Capital, PTX Capital and Nor’easter Ventures. The company, which focuses on developing new types of anti-infective drugs to best antimicrobial...
Automata, an automation company helping life sciences innovate, diagnose and discover at scale, today announced a $50 million (£36.8M) raise in Series B funding.
The round was led by Octopus Ventures with participation from returning investors Hummingbird, Latitude Ventures, ABB Technology Ventures, Isomer Capital as well as strategic investors including In-Q-Tel.
WHAT IT DOES
The firm’s Automata...
DeepCure, developer of small molecule therapeutics using an AI-enabled drug discovery platform, raised $40 million in Series A funding.
The round was led by Morningside Ventures with participation from existing investors TLV Partners, Sapir Venture Partners and Benon Group Ltd.
DeepCure said the Series A brings its total raise to $47 million.
WHAT IT DOES
The company uses its AI engine to develop...